Gritstone Oncology, Inc.
5858 Horton Street, Suite 210
Emeryville, California 94608
November 6, 2019
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
| Attention: | Folake Ayoola, Senior Counsel, Office of Life Sciences |
Irene Paik, Attorney Advisor
| Re: | Gritstone Oncology, Inc. Registration Statement on Form S-3 (Registration No. 333-234211) |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-234211) (the “Registration Statement”) of Gritstone Oncology, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on November 8, 2019, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Brian Cuneo at (650) 463-3014.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| GRITSTONE ONCOLOGY, INC. | ||
| By: | /s/ Jean-Marc Bellemin | |
| Jean-Marc Bellemin | ||
| Chief Financial Officer | ||
| CC: | Andrew Allen, M.D., Ph.D., Gritstone Oncology, Inc. |
Jean-Marc Bellemin, Gritstone Oncology, Inc.
Alan C. Mendelson, Esq., Latham & Watkins LLP
Brian J. Cuneo, Esq., Latham & Watkins LLP
Alexander T. White, Esq., Latham & Watkins LLP